Premium
Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia
Author(s) -
Shih HungJen,
Huang ChunJen,
Lin JuiAn,
Kao MingChang,
Fan YenChun,
Tsai PeiShan
Publication year - 2018
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.23451
Subject(s) - medicine , cohort , hazard ratio , hyperlipidemia , cohort study , diabetes mellitus , population , proportional hazards model , confidence interval , endocrinology , environmental health
Background A high fat diet is associated with risk of benign prostatic hyperplasia (BPH). However, whether hyperlipidemia is associated with BPH remains unclear. This population‐based cohort study elucidated whether hyperlipidemia is associated with an increased risk of BPH. Methods We used a new‐exposure design and analyzed data retrieved from the Taiwan National Health Insurance Database between January 1, 2000 and December 31, 2013. The cohort of men with newly diagnosed hyperlipidemia and the age‐ and index‐date‐matched (1:3) nonhyperlipidemia cohort were tracked for incidence of BPH during a 1‐ to 14‐year follow‐up. Diagnosis of BPH using the International Classification of Diseases, Ninth Revision, Clinical Modification codes, and the occurrence of BPH diagnosis plus the use of alpha‐blockers or 5‐alpha reductase inhibitors or receipt of transurethral resection of the prostate were the primary and secondary endpoints, respectively. The confounders in this study were diabetes mellitus, hypertension, coronary heart disease, obesity, liver cirrhosis, nonsteroidal anti‐inflammatory drugs, metformin, aspirin, and number of urologist visits. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards regression model adjusted for the propensity score. Results A total of 35 860 subjects (aged 40‐99 years)—including the hyperlipidemia cohort ( n = 8,965) and nonhyperlipidemia cohort ( n = 26 895)—were identified. Our data revealed that the hyperlipidemia cohort had significantly higher incidences of developing BPH (24.6% vs 12.3%, P < 0.001) and treated BPH (13% vs 5.7%, P < 0.001) compared with the nonhyperlipidemia cohort. The risk of developing BPH in the hyperlipidemia cohort was significantly higher than that in the nonhyperlipidemia cohort (HR = 1.73, 95% CI = 1.63‐1.83, P < 0.001) after adjustment for the propensity score. Conclusions Hyperlipidemia is associated with an increased risk of clinical BPH.